Description
/* Reset & Base */
* {
box-sizing: border-box;
margin: 0;
padding: 0;
}
body {
font-family: ‘Inter’, -apple-system, BlinkMacSystemFont, ‘Segoe UI’, Roboto, Helvetica, Arial, sans-serif;
background: #fff;
color: #1e1e1e;
line-height: 1.6;
}
/* Brand Tokens */
:root {
–sm-orange: #F27444;
–sm-orange-soft: #fff4ef;
–sm-orange-border: #ffd9cb;
–sm-violet: #7256d8;
–sm-violet-soft: #f6f3ff;
–sm-violet-border: #ddd4ff;
–sm-green: #229a5b;
–sm-green-soft: #f4fff8;
–sm-line: #f0e8e4;
–sm-ink: #111;
–sm-muted: #555;
–sm-panel: #fcfaf9;
}
/* Utilities */
.sm-container {
max-width: 1300px;
margin: 0 auto;
padding: 20px 32px 60px;
width: 100%;
}
.sm-grid-2 {
display: grid;
grid-template-columns: 1fr 1fr;
gap: 40px;
}
.sm-grid-3 {
display: grid;
grid-template-columns: repeat(3, 1fr);
gap: 24px;
}
.sm-grid-4 {
display: grid;
grid-template-columns: repeat(4, 1fr);
gap: 20px;
}
/* Tabs */
.sm-tab-input,
.sm-panel {
display: none;
}
#sm-tab-product:checked ~ .sm-tab-nav label[for=”sm-tab-product”],
#sm-tab-disclaimer:checked ~ .sm-tab-nav label[for=”sm-tab-disclaimer”] {
background: var(–sm-orange);
color: #fff;
border-color: var(–sm-orange);
box-shadow: 0 8px 20px rgba(242, 116, 68, 0.25);
}
#sm-tab-product:checked ~ .sm-product-panel,
#sm-tab-disclaimer:checked ~ .sm-disclaimer-panel {
display: block;
}
.sm-tab {
font-size: 1rem;
padding: 12px 32px;
border-radius: 999px;
background: #fff;
border: 1px solid #e0d6d0;
color: #1e1e1e;
cursor: pointer;
font-weight: 650;
transition: all 0.2s;
user-select: none;
}
.sm-tab:hover {
background: var(–sm-orange-soft);
border-color: var(–sm-orange);
}
/* Hero */
.sm-hero-bg {
position: relative;
overflow: hidden;
border-radius: 34px;
padding: 34px;
background:
radial-gradient(circle at 84% 20%, rgba(114, 86, 216, 0.12), transparent 34%),
radial-gradient(circle at 12% 85%, rgba(242, 116, 68, 0.10), transparent 38%),
linear-gradient(135deg, #fff 0%, #fffaf7 52%, #f8f6ff 100%);
border: 1px solid #f2e8e2;
}
.sm-hero-title {
font-size: 44px;
line-height: 1.08;
font-weight: 820;
color: var(–sm-ink);
margin: 0 0 10px;
letter-spacing: -0.03em;
}
.sm-kicker {
font-size: 0.86rem;
letter-spacing: 0.11em;
text-transform: uppercase;
color: var(–sm-orange);
font-weight: 750;
margin-bottom: 8px;
}
/* Chips */
.sm-chip {
display: inline-block;
padding: 8px 16px;
border-radius: 999px;
background: var(–sm-orange-soft);
border: 1px solid var(–sm-orange-border);
color: var(–sm-orange);
font-weight: 650;
font-size: 0.9rem;
margin: 4px 6px 4px 0;
letter-spacing: 0.01em;
}
.sm-chip-violet {
background: var(–sm-violet-soft);
border-color: var(–sm-violet-border);
color: var(–sm-violet);
}
.sm-chip-neutral {
background: #fff;
border-color: #e8dfda;
color: #333;
}
/* Cards */
.sm-card {
background: #fff;
border: 1px solid var(–sm-line);
border-radius: 28px;
padding: 28px;
transition: transform 0.2s ease, box-shadow 0.2s ease, border-color 0.2s ease;
}
.sm-card:hover {
transform: translateY(-4px);
box-shadow: 0 20px 40px -12px rgba(0, 0, 0, 0.08);
border-color: var(–sm-orange);
}
.sm-card-violet:hover {
border-color: var(–sm-violet);
}
.sm-dual-card {
background: rgba(255, 255, 255, 0.88);
backdrop-filter: blur(8px);
border: 1px solid rgba(255, 255, 255, 0.95);
box-shadow: 0 18px 50px rgba(70, 50, 120, 0.09);
}
.sm-component {
border-radius: 22px;
padding: 22px;
border: 1px solid var(–sm-line);
}
.sm-component-tesa {
background: linear-gradient(145deg, #fff8f4, #fff);
border-color: var(–sm-orange-border);
}
.sm-component-ipa {
background: linear-gradient(145deg, #f7f4ff, #fff);
border-color: var(–sm-violet-border);
}
.sm-plus-badge {
width: 44px;
height: 44px;
border-radius: 50%;
display: grid;
place-items: center;
margin: 14px auto;
background: #111;
color: #fff;
font-size: 24px;
font-weight: 750;
}
/* Pathway Diagram */
.sm-pathway {
display: grid;
grid-template-columns: 1fr auto 1fr;
align-items: stretch;
gap: 16px;
margin-top: 22px;
}
.sm-pathway-arrow {
display: grid;
place-items: center;
color: #777;
font-size: 26px;
}
/* Specs */
.sm-spec-wrap {
border: 1px solid var(–sm-line);
border-radius: 28px;
overflow: hidden;
margin-bottom: 48px;
background: #fff;
}
.sm-spec-head,
.sm-spec-row {
display: grid;
grid-template-columns: 1.05fr 1fr 1fr;
}
.sm-spec-head > div {
padding: 18px 20px;
font-weight: 780;
color: #fff;
}
.sm-spec-head > div:first-child {
background: #222;
}
.sm-spec-head > div:nth-child(2) {
background: var(–sm-orange);
}
.sm-spec-head > div:nth-child(3) {
background: var(–sm-violet);
}
.sm-spec-row > div {
padding: 15px 20px;
border-bottom: 1px solid var(–sm-line);
}
.sm-spec-row:nth-child(odd) {
background: #fcfaf9;
}
.sm-spec-row:last-child > div {
border-bottom: 0;
}
.sm-blend-spec-grid {
display: grid;
grid-template-columns: 1fr 1fr;
}
.sm-blend-spec-item {
padding: 16px 22px;
border-bottom: 1px solid var(–sm-line);
background: #fff;
}
.sm-blend-spec-item:nth-child(odd) {
background: #fcfaf9;
}
/* Notices */
.sm-notice {
border-radius: 28px;
padding: 30px;
margin-bottom: 44px;
}
.sm-notice-coa {
background: var(–sm-green-soft);
border: 2px solid #44bd7a;
}
.sm-notice-limit {
background: #fffaf0;
border: 1px solid #f1cf83;
}
.sm-status {
display: inline-block;
border-radius: 999px;
padding: 5px 13px;
font-size: 0.78rem;
font-weight: 780;
letter-spacing: 0.04em;
}
.sm-status-green {
background: var(–sm-green);
color: #fff;
}
.sm-status-amber {
background: #b06d00;
color: #fff;
}
/* FAQ */
.sm-faq summary::-webkit-details-marker {
display: none;
}
.sm-faq[open] .sm-plus {
transform: rotate(45deg);
}
/* Reference list */
.ref-item {
padding: 16px 20px;
background: #fff;
border-radius: 16px;
border: 1px solid var(–sm-line);
transition: all 0.2s ease-in-out;
}
.ref-item:hover {
border-color: var(–sm-orange);
box-shadow: 0 4px 12px rgba(242, 116, 68, 0.08);
}
.ref-item a {
color: var(–sm-orange);
font-weight: 720;
text-decoration: none;
}
.ref-item a:hover {
text-decoration: underline;
}
/* Responsive */
@media (max-width: 900px) {
.sm-pathway {
grid-template-columns: 1fr;
}
.sm-pathway-arrow {
transform: rotate(90deg);
}
.sm-spec-head,
.sm-spec-row {
grid-template-columns: 1fr;
}
.sm-spec-head > div:first-child,
.sm-spec-head > div:nth-child(2),
.sm-spec-head > div:nth-child(3) {
background: #222;
}
.sm-spec-row > div {
border-bottom: 1px solid var(–sm-line);
}
}
@media (max-width: 768px) {
.sm-container {
padding: 20px 16px 40px;
}
.sm-grid-2,
.sm-grid-3,
.sm-grid-4,
.sm-blend-spec-grid {
grid-template-columns: 1fr !important;
gap: 20px;
}
.sm-tab {
width: 100%;
text-align: center;
}
.sm-hero-title {
font-size: 32px;
}
.sm-hero-bg {
padding: 24px;
}
h2 {
font-size: 24px !important;
}
}
SaiyanMed Dual-Pathway Research Blend
Tesamorelin + Ipamorelin Blend
Tesamorelin 10 mg + Ipamorelin 5 mg per vial · 15 mg total
A co-lyophilized research blend pairing a 44-amino-acid GHRH analog with a selective
ghrelin/growth-hormone-secretagogue receptor agonist. The formulation is intended for
qualified laboratory investigation of GHRHR and GHS-R1a signaling, secretagogue
interaction, and GH-axis research models. Lot release should be supported by
component-specific HPLC, mass-spectrometry identity data, and batch-matched third-party
documentation. For research use only — not for human or veterinary use.
Tesamorelin 10 mg
Ipamorelin 5 mg
15 mg Total / Vial
Co-Lyophilized
Lot-Specific COA
Two Distinct Receptor Systems
Component A
Tesamorelin · 10 mg
Full-length GHRH(1-44) analog · GHRHR pathway
+
Component B
Ipamorelin · 5 mg
Selective pentapeptide secretagogue · GHS-R1a pathway
The exact SaiyanMed blend is a research formulation and is not an FDA-approved drug product.
Research Context
What is the Tesamorelin + Ipamorelin Blend?
Tesamorelin is a synthetic analog of the 44-amino-acid human growth-hormone-releasing
factor sequence, modified with an N-terminal hexenoyl moiety. Published FDA labeling
describes tesamorelin as binding and stimulating human GRF/GHRH receptors.
Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, described in
peer-reviewed research as a selective growth-hormone secretagogue acting through the
ghrelin/growth-hormone-secretagogue receptor system.
Earlier studies of GHRH and GHRP-class ligands—not studies of this exact commercial
formulation—reported potentiated or synergistic GH release in experimental models.
Accordingly, this blend is positioned as a tool for comparative, receptor-pathway, and
secretagogue-interaction research rather than as evidence of efficacy in humans.
Pathway Map
Complementary Inputs, Separate Targets
Tesamorelin
GHRH analog → GHRHR signaling
→
Ipamorelin
GHS ligand → GHS-R1a signaling
Interpretation boundary:
Receptor complementarity is a mechanistic research rationale. It does not establish
safety, clinical benefit, or an approved therapeutic combination.
🧪 Research Applications
01
Dual-Receptor Signaling
Experimental comparison of GHRHR and GHS-R1a inputs within GH-axis models.
02
Combination Interaction
GHRH-class versus GHRP-class responses, alone and in combination, under controlled protocols.
03
Somatotroph Signaling
Laboratory study of secretagogue-dependent signaling and GH-release kinetics.
04
Receptor Selectivity
Use of ipamorelin as a selective GHS reference ligand in comparative endocrine models.
05
Analytical Characterization
Component identity, purity, blend-ratio, recovery, and stability-method development.
06
Comparative Secretagogue Models
Cross-comparison with single-component or alternative GHRH/GHRP research standards.
📊 Component Specifications
Attribute
Tesamorelin
Ipamorelin
Amount per vial
10 mg
5 mg
CAS number
218949-48-5
170851-70-4
Development code
TH9507
NNC 26-0161
Class
Synthetic GHRH/GRF analog
Selective growth-hormone secretagogue pentapeptide
Sequence / structure
44-amino-acid human GRF sequence with an N-terminal hexenoyl moiety
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular formula
C221H366N72O67S (free-base moiety)
C38H49N9O5
Molecular weight
5135.9 Da (free-base equivalent; FDA label)
711.9 g/mol (PubChem)
Primary research target
GHRH/GRF receptor (GHRHR)
Ghrelin/growth-hormone-secretagogue receptor (GHS-R1a)
PK reference note
Current FDA labeling reports a mean 11-minute elimination half-life for EGRIFTA WR after a specific SC regimen; this is formulation-specific reference data.
Human PK/PD has been published, but no single half-life value is asserted here for this co-lyophilized blend.
🧬 Blend-Level Specifications
Form: Co-lyophilized powder, white to off-white
Fill per vial: 10 mg tesamorelin + 5 mg ipamorelin
Total peptide content: 15 mg per vial
Pack configuration: 10 vials per kit
Purity target: ≥99% by HPLC for each component, verified by lot documentation
Identity target: Component-specific mass-spectrometry confirmation
Blend-ratio control: Confirmed against batch manufacturing and analytical records
COA: Batch-matched third-party documentation for both components
Release status: QC-released under SaiyanMed laboratory specifications
Intended use: Research use only; not a pharmaceutical product
Recommended sealed storage: −20°C, protected from light and moisture, unless lot documentation states otherwise
Shelf-life claim: Use the expiration date and stability statement shown on the lot-specific label/COA
VERIFY BOTH COMPONENTS
Batch Documentation
Lot-Matched Third-Party COA Review
A blend COA should identify the finished lot and provide traceable analytical evidence for
both tesamorelin and ipamorelin. Before research use, confirm that the report matches the
vial lot, the stated 10 mg + 5 mg composition, the HPLC result for each component, and the
relevant mass-spectrometry identity data.
When a third-party lab report is supplied, validate the report identifier through the
SaiyanMed Trust Center
.
Do not display a “verified” status on the storefront unless a current, batch-specific report
is actually published and the public verification link resolves correctly.
FORMULATION LIMITATION
Important scientific distinction
Public sources support the individual chemical identities and the general mechanistic
rationale for combining GHRH- and GHRP-class ligands. They do not establish the stability,
pharmacokinetics, safety, or efficacy of this exact 10 mg + 5 mg co-lyophilized SaiyanMed
formulation. Those product-specific claims require batch analytics and formulation-specific
validation.
📦 Storage & Laboratory Handling
🧊 Sealed Vials
Store sealed lyophilized vials at −20°C, protected from light and
moisture, unless the lot-specific label or COA provides a different validated condition.
Keep containers tightly closed and avoid repeated temperature cycling.
💧 Reconstitution for Research
Reconstitute only under an institutionally approved laboratory protocol using the
protocol-defined diluent and volume. Add diluent slowly along the vial wall and mix by
gentle swirling; do not shake or vortex. Record the final concentration, diluent,
preparation date, and storage condition.
Post-Reconstitution Stability
Refrigerated storage at 2–8°C may be used only when supported by the chosen diluent,
validated laboratory protocol, and lot/formulation stability data. A universal “2–4 week”
stability period is not asserted for this blend. Discard material showing cloudiness,
discoloration, visible particles, container damage, or an undocumented storage excursion.
🚚 Fulfillment & Transit Notice
Fulfillment origin: Orders are routed from the nearest available logistics
location. Domestic US orders may be fulfilled from a US warehouse; international orders may
ship from the China logistics warehouse. Estimated international transit is generally
7–14 business days, subject to carrier and customs processing.
Temperature in transit: The product is shipped in lyophilized form with
protective packaging. On receipt, inspect the vial and transfer it promptly to the stated
sealed-storage condition. Transit statements do not replace lot-specific stability data.
Customs: Cross-border shipments of research materials may be inspected,
delayed, assessed duties, or require consignee documentation. Import compliance remains the
consignee’s responsibility.
Damage, mismatch, or delay: Retain the packaging, vial label, shipping label,
and clear photographs, then contact SaiyanMed with the order reference within the applicable
policy period.
⚠️
Research Use Only
This dual-secretagogue blend is supplied solely for qualified laboratory research and is
not intended for human or veterinary administration.
Strict Use Limitation
Not a Drug, Medicine, Supplement, or Consumer Product
This product has not been evaluated as a finished combination product for diagnosis,
treatment, prevention, mitigation, or cure of any disease. It is not equivalent to an
FDA-approved tesamorelin product and no approved ipamorelin drug is represented by this page.
No statement on this page should be interpreted as a recommendation for injection,
dosing, personal use, athletic performance, anti-aging, weight management, or body
composition modification.
✅ Purchaser Attestation
✓ The purchaser is a qualified researcher or is operating under qualified scientific supervision.
✓ The material will be used only within a legitimate, documented research protocol.
✓ The purchaser will review the lot label, COA, SDS, and institutional requirements before use.
✓ The purchaser accepts responsibility for lawful acquisition, storage, handling, and disposal.
No efficacy or suitability warranty: Research outcomes depend on experimental
design, material handling, analytical method, biological system, and other variables. Product
documentation does not guarantee a particular biological result.
🛡️ General Laboratory Controls
🚫 No Personal Use
Do not administer to humans or animals and do not use outside a controlled research setting.
🥽 PPE & Containment
Apply appropriate gloves, eye protection, protective clothing, and institutional containment measures.
🧾 Lot Traceability
Record vial lot, COA identifiers, preparation details, operators, and storage history.
🧪 Method Suitability
Validate analytical methods for both components and account for blend-specific interference.
🗑 Controlled Disposal
Dispose of unused material, solutions, and contaminated supplies under applicable laboratory rules.
⚖️ Jurisdictional Compliance
Confirm local requirements before purchase, import, possession, transfer, or experimental use.
💬 Frequently Asked Questions
What is in each vial?
+
Each vial is specified to contain 10 mg of tesamorelin and 5 mg of ipamorelin, for 15 mg total,
in a co-lyophilized research formulation.
Why are tesamorelin and ipamorelin combined?
+
They are used as research ligands for different receptor systems: tesamorelin for GHRHR and
ipamorelin for GHS-R1a. Published GHRH/GHRP studies provide a mechanistic basis for examining
combined-pathway effects, but those studies do not validate the safety or efficacy of this exact blend.
Is this blend the same as EGRIFTA?
+
No. EGRIFTA products are FDA-approved tesamorelin formulations with their own compositions,
labeling, storage conditions, and approved use. This SaiyanMed product is a tesamorelin-plus-ipamorelin
research blend and is not an approved drug product.
How should the COA be checked?
+
Match the finished-product lot on the vial to the report, confirm the 10 mg + 5 mg composition,
review HPLC results and mass-spectrometry identity evidence for both components, and validate any
third-party report through its official verification portal.
How should sealed vials be stored?
+
SaiyanMed’s general laboratory guidance is −20°C, sealed and protected from light and moisture,
unless the lot-specific label or COA states a different validated condition. Post-reconstitution
storage must follow the selected diluent and the laboratory’s validated protocol.
Is this intended for human or veterinary use?
+
No. It is supplied strictly for laboratory research and is not intended for administration,
diagnosis, treatment, disease prevention, performance enhancement, or personal use.
Where may orders be fulfilled from?
+
Domestic US orders may be routed through US warehouse fulfillment, while international orders may
ship from the China logistics warehouse. Routing, delivery estimates, import requirements, and
customs processing depend on destination and carrier conditions.
📚 Scientific & Regulatory References
References below support component identity, known receptor pharmacology, or the general GHRH/GHRP
research rationale. They do not constitute validation of the exact SaiyanMed 10 mg + 5 mg finished blend.
U.S. FDA — EGRIFTA WR Prescribing Information (revised March 2025):
Official description of tesamorelin, its 44-amino-acid GRF sequence, N-terminal hexenoyl moiety,
free-base-equivalent molecular weight, receptor pharmacology, and formulation-specific pharmacokinetics.
View FDA labeling ↗
PubChem — Tesamorelin, CID 16137828:
Public chemical record for tesamorelin, including molecular formula, identifiers, and linked data sources.
View PubChem record ↗
PubChem — Ipamorelin, CID 9831659:
Public chemical record listing ipamorelin, CAS 170851-70-4, molecular formula C38H49N9O5,
and molecular weight approximately 711.9 g/mol.
View PubChem record ↗
Raun K, Hansen BS, Johansen NL, et al. (1998):
Ipamorelin, the first selective growth hormone secretagogue.
European Journal of Endocrinology, 139(5), 552–561. PMID 9849822.
View at PubMed ↗
Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. (1999):
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
Pharmaceutical Research, 16(9), 1412–1416. PMID 10496658.
View at PubMed ↗
Cheng K, Chan WW, Barreto A Jr, Convey EM, Smith RG. (1989):
The synergistic effects of a growth-hormone-releasing peptide on GRF-stimulated GH release in rat primary pituitary cell culture.
Endocrinology, 124(6), 2791–2798. PMID 2541999.
View at PubMed ↗
Falutz J, Allas S, Blot K, et al. (2007):
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
New England Journal of Medicine, 357, 2359–2370. PMID 18057338.
This clinical tesamorelin paper is cited for the tesamorelin literature record, not for this blend.
View at PubMed ↗





Reviews
There are no reviews yet.